Community Research and Development Information Service - CORDIS

  • European Commission
  • CORDIS
  • Publications
  • Periodic Report - CAREPNEUMO (Combating Antibiotics Resistant Pneumococci by Novel Strategies Based on in vivo and in vitro Host Pathogen Interactions)
FP7

Periodic Report - CAREPNEUMO (Combating Antibiotics Resistant Pneumococci by Novel Strategies Based on in vivo and in vitro Host Pathogen Interactions)

Project ID: 223111
Funded under: FP7-HEALTH

Abstract

This is the periodic report for 'Combating antibiotics resistant pneumococci by novel strategies based on in vivo and in vitro host pathogen interactions' (CAREPNEUMO). Their aim is to apply a multi-disciplinary approach that includes epidemiology, host-pathogen interactions, infection models and intervention strategies to combat antibiotic resistant Streptococcus pneumoniae. The consortium brings together 12 research organisations and 1 SME with expertise in the above-mentioned areas.

To determine the role of surface exposed lipoproteins a number of mutants were constructed for further analysis. A murine model for pneumococcal infections was established and is now being used to determine the virulence potential of different clinical isolates collected in epidemiology work packages. In intervention section, the consortium identified new pneumococcal targets for development of a new generation of antimicrobials against resistant pneumococci.

The prevention strategies of CAREPNEUMO include the development of a novel polysaccharide-glycolipid conjugate vaccine and a protein based universal vaccine. The conjugated vaccine was based on serotype 4 conjugated with alpha GalCer which gave high titers of IgG and IgM against S. pneumoniae, indicating that alpha GalCer is a potent adjuvant. Reverse vaccinology using patient sera led to the identification of a number of peptides with features of a promising vaccine candidate.

Download application/pdf (202423)

Related information

Record Number: 10789 / Last updated on: 2012-07-23
Category: PROJ